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ABSTRACT

The presently-disclosed subject matter includes methods
and devices for diagnosing, prognosing, and treating brain
damage in a subject, including brain damage caused by
stroke or a traumatic brain injury (TBI). The methods can
comprise providing a sample obtained from the subject,
exposing the sample to an antibody selective for a visininlike protein, detecting the presence of a complex that
includes the antibody and the visinin-like protein, and diagnosing and/or prognosing the subject as having brain damage if there is the presence of the complex. Embodied
methods can also comprise administering a treatment for
brain damage if the subject includes the presence of the
visinin-like protein.
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METHODS AND SYSTEMS FOR PROGNOSIS
AND DIAGNOSIS OF BRAIN DAMAGE

that lasts more than 24 hours, and generally demonstrate
GCS scores of 14 or 15. Therefore, mild TBI is difficult to
diagnose because mild TBI can present limited injury and
only subtle changes in GCS scores. Patients with moderate
TBI generally have a loss of consciousness that lasts greater
than 30 minutes, have post injury anmesia, and generally
demonstrate GCS scores of 9 to 12. On the other hand,
patients with severe TBI, which typically include victims of
poly-trauma, are relatively easier to diagnose when compared to patients having mild and moderate injuries.
Because of difficulties associated with clinical diagnosis
of mild and moderate TBI and stroke, others have attempted
to develop biochemical and surrogate markers of TBI that
can be measured in circulating fluids, diagnose the extent of
injury, and define the anatomical and cellular pathology
associated with injury. Current biomarkers of TBI are classified by their pathophysiological role and include molecules
involved in neuroinflmation, glial activation, neuron dysfunction/degeneration, and markers of oxidative stress.
Known biomarkers include creatine kinase (CK), glial fibrillary protein (GFAP), lactate dehydrogenase (LDH), myelin
basic protein (MBP), neuron specific enolase (NSE), S100~,
and markers of neuroinflammation.
However, known biomarker have limited capabilities For
instance, even though known biomarkers may identifY subjects having experienced a stroke from normal subjects,
known biomarkers are not capable of delineating between
ischemic stroke patients and patients having experienced a
hemorrhagic stroke, seizure, migraine, syncope, hypoglycemia, and the like. Furthermore, although some biomarkers
have been identified as potentially being useful for characterizing brain damage, most known biomarkers are quantified using time-consuming techniques, such as enzyme
linked immunoassays (ELISAs) that can take as long as 24
hours to complete. Therefore, known techniques provide
limited information on a subject only after an optimal time
period for treatment has passed.
Hence, there remains a need for a biomarker that can be
used for the diagnosis and prognosis of brain damage. There
also remains a need for systems that can be used to identifY
and measure biomarkers in a sample collected from a subject
within a clinically relevant time period.

RELATED APPLICATIONS
This application claims priority from U.S. Provisional
Patent Application No. 61/860,645, filed Jul. 31, 2013, the
entire disclosure of which is incorporated herein by this
reference.
TECHNICAL FIELD
The presently-disclosed subject matter relates to methods
and systems for prognosis, diagnosis, and treatment of brain
damage in a subject. In particular, the presently-disclosed
subject matter relates to methods and systems for prognosing, diagnosing, and treating brain damage that include
measuring levels ofvisinin-like family proteins in a biological sample obtained from a subject.
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INTRODUCTION
Traumatic brain injury (TBI) is a significant civilian and
military hearth concern. Brain injury can exist in individuals
who experience concussive or sub-concussive blows to the
head, and has particular relevance to athletic and military
activities. Without reliable diagnostics that can determine
whether a blow to the head affected the brain, athletes and
soldiers can return to their sport or to combat and be exposed
to additional injuries which may be associated with chronic
and progressive symptoms and neuropathologic damage.
Similarly, about 795,000 Americans suffer a stroke each
year, and stoke is a leading cause of serious long-term
disability. Ischemic strokes, due to blocked blood vessels in
the brain, account for about 87% of all strokes.
Current diagnostic and prognostic tools used for evaluation ofTBI and stroke remain limited particularly for in field
(i.e., pre-hospital) evaluation. Central to the clinical diagnosis ofTBI is the use of non-contrast computer tomography
(CT) and magnetic resonance imaging (MRI). Non-contrast
CT is generally the initial test for diagnosis of TBI because
of its availability at most healthcare facilities. Although CT
is sensitive in the identification of acute hemorrhage and
fracture associated with severe injury, it is relatively insensitive in the identification of diffuse injury associated with
milder TBI. Also, CT scans often appear to be normal after
the onset of an ischemic stroke and may remain normal for
hours after the event. MRI is capable of detecting hematomas, small contusions, and ischemic events not captured by
CT, but it is relatively insensitive to diffuse axonal injury and
may not be feasible in all situations.
Furthermore, the time delay associated with current diagnostic approaches for stroke patients limits the time during
which thrombolytics (tissue plasminogen activator; t-PA)
may be administered. Administration oft-PA improves neurologic outcomes in patients with ischemic stroke, but the
therapeutic window can be less than 6 hours after the event
and can be as few as 2 or 3 hours post ischemia. Because of
the potential detrimental effects of use oft-PA in patients
with a small hemorrhagic stroke, the lack of a diagnostic that
can quickly differentiate between hemorrhagic and ischemic
stroke is associated with underuse of fibrinolytic treatment.
Determination of the Glasgow Coma Scale (GCS) is also
used to diagnose the degree of brain injury. Patients with
mild TBI generally have no penetrating injuries of the head
or other organs, experience less than 30 minutes of lost or
altered consciousness, may demonstrate post-injury anmesia
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BRIEF DESCRIPTION OF THE DRAWINGS
The novel features of the presently-disclosed subject
matter are set forth with particularity in the appended claims.
A better understanding of the features and advantages of the
presently-disclosed subject matter will be obtained by reference to the following detailed description that sets forth
illustrative embodiments, in which the principles of the
invention are used, and the accompanying drawings of
which:
FIG. 1 includes a schematic showing an embodiment of a
lateral flow device (LFD) comprising a laminate backing
(A), a detection portion (B), a wicking portion (C), a
conjugate portion (D), and a sample portion (E), wherein a
VILIP-1 K-25 antibody is deposited as a stripe left of 'B',
Goat Serum is deposited as a stripe right of 'B', and
conjugate that includes nanogold beads labeled with
VILIP-1 PL-A2 is illustrated as a shaded area on 'D'.
FIG. 2 includes images showing VILIP-1 levels in normal
control serum measured using a lateral flow device.
FIG. 3 includes images showing VILIP-1 levels for ischemic stroke, mild traumatic brain injury (TBI), and moderate
TBI samples from animal subjects.
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FIG. 4 includes a plot showing mean±standard error of the
mean (SEM) VILIP-1 levels in rats subjected to an ischemic
event induced by suture occlusion of the middle cerebral
artery pre-injury, at the end of the 1 hour of occlusion, 15
minutes after the initiation of reperfusion, and 24 hours post
reperfusion.
FIG. 5 includes a plot showing receiver operating characteristic (ROC) curves for VILIP-1 levels in serum samples
from rats subjected to middle cerebral artery occlusion as a
model of ischemic stroke.
FIG. 6 shows mean±SEM VILIP-1 levels in serum from
surgery naive rats or rats subjected to mild or moderate TBI
that were taken 1, 3, and 4 hours post injury.
FIG. 7 includes a chart showing receiver operating characteristic (ROC) curves for VILIP-1 levels in serum samples
from rats that were taken 1, 3, and 4 hours following mild
or moderate TBI.
FIG. 8 includes a chart showing VILIP-1 levels in serum
from two subjects with hemorrhagic stroke and two subjects
with ischemic stroke.
FIG. 9 includes a chart showing VILIP-1 levels relative to
infarct volume for two subjects with hemorrhagic stroke and
two subjects with ischemic stroke.

subjected to qualitative and/or quantitative measurements to
determine whether there is an absence, presence, and/or
particular concentration of a component. In some instances
the sample includes a circulating fluid, and can include a
fluid that circulates within the central nervous system.
Exemplary types of biological samples include serum,
blood, plasma, cerebrospinal fluid, and the like. The sample
may or may not include cells from the subject. Depending on
the type of sample obtained for a particular method, any
suitable known method can be used to obtain the sample
from the subject. The volume of a sample is also not
particularly limited, and is about 10 f.LL to about 1,000 mL
in some of the presently-disclosed embodiments.
The term "subject" is not particularly limited, and is
inclusive of a vertebrates, such as mammals. The term
"subject" includes human and veterinary subjects. Thus, the
subject of the herein disclosed methods can be a human,
non-human primate, horse, pig, rabbit, dog, sheep, goat,
cow, cat, guinea pig, rodent, or the like. The term does not
denote a particular age or sex. Thus, adult and newborn
subjects, as well as fetuses, whether male or female, are
intended to be covered.
The terms "diagnosing," "diagnosis," and the like as used
herein refer to methods by which the skilled artisan can
estimate and even determine whether or not a subject is
suffering from a given disease or condition. Along with
diagnosis, "prognosis," "prognosing," and the like are also
an area of great concern and interest, and can refer to
predicting a clinical outcome (with or without medical
treatment), selecting an appropriate treatment (or whether
treatment would be effective), or monitoring a current treatment and potentially changing the treatment, based on the
presence of a visinin-like protein. The terms "diagnose" and
"prognosis" can refer to the ability to determine or predict
the course or outcome of a condition with up to 100%
accuracy, or predict that a given course or outcome is more
or less likely to occur. In certain embodiments, a diagnosis
or prognosis is indicative of an about 10%, about 20%, about
30%, about 40%, about 50%, about 60%, about 70%, about
80%, or about 90% chance that the subject has brain
damage. If an accurate diagnosis and/or prognosis can be
made, appropriate therapy, and in some instances less severe
therapy or more effective therapy, for the subject can be
chosen. In some embodiments of the presently-disclosed
subject matter, a method includes identifying a subject as
having brain damage, possible due to TBI or a stroke, if a
sample obtained from the subject includes a presence of a
visinin-like protein.
In the various methods and system described herein, the
visinin-like protein can be selected from the group consisting of VILIP-1, VILIP-2, VILIP-3, hippocalcin, neurocalin
delta, and combinations thereof. The terms "polypeptide",
"protein", and "peptide", which are used interchangeably
herein, refer to a polymer of the protein amino acids
regardless of its size or function. The terms "protein",
"polypeptide", and "peptide" are used interchangeably
herein to also refer to a gene product, homologs, orthologs,
paralogs, fragments, any protease derived peptide (fragment), and other equivalents, variants, and analogs of a
polymer of amino acids.
In general, calcium balance is maintained in the central
nervous system by either Ca buffering or Ca sensing proteins. As mentioned above, the visinin-like protein family
represents a specific subfamily of brain associated Ca2 +sensors that include VILIP-1, VILIP-2, VILIP-3, hippocalcin, and neurocalin delta. These proteins possess 4 EF -hand
Ca 2 +-binding moieties that, upon Ca2 + binding, lead to

DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
The presently-disclosed subject matter relates to methods
and systems for diagnosing, prognosing, and/or treating
brain damage, including brain damage caused by a stroke
and/or a traumatic brain injury (TBI). The present inventors
have identified biomarkers that can effectively diagnose and
prognose such brain damage. In some instances, the biomarkers of TBI or stroke be based on substrates that are
relevant and/or specific to the central nervous system and
should provide information about injury mechanisms.
In some instances, the biomarkers be measurable in
accessible biological fluids, such as cerebrospinal fluid and
blood, and should correlate with the severity of injury and
resulting functional deficits. Additionally, exemplary biomarkers have high sensitivity for identification of subjects
(i.e., high positive identification), high specificity (i.e., low
false positive identifications), and have an appearance profile that follows neuronal/glial injury. In this regard, the
present inventors have found that visinin-like proteins
(VILIPs) can serve as biomarkers for brain damage.
Diagnosis and Prognosis
The presently-disclosed subject includes methods for
diagnosing and/or prognosing brain damage in a subject.
Exemplary methods include providing a biological sample
obtained from the subject, and subsequently determining a
presence of a visinin-like protein in the sample obtained
from the subject, the presence of the visinin-like protein
indicating that the subject has brain damage. The terms
"biological sample" and "sample" are used interchangeably
herein to generally refer to a sample that is intended to be
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regulation of cyclic nucleotide levels, modulation of voltage
gated Ca2 + and A type K+ channels, transcriptional repression, kinase modulation, and neurotransmitter release.
For example, VILIP-1 in neurons undergoes a Ca2 +dependent association with the plasma membrane or Golgi
membranes and has modulatory effects on signaling of
cAMP and cGMP. In addition, VILIP-1 modulates activity
of guanyl cyclase B through clathrin-dependent receptor
cycling and plays a role in regulation of gene expression by
binding double stranded RNA. In human brain, VILIP-1
protein has been demonstrated in the prefrontal, cingulate,
insular and temporal cortices, putamen, nucleus accumbens
but not caudate. In the hippocampus, VILIP-1 is present in
a subset of pyramidal neurons in CAl and CA4 but is not
observed in CA2 or CA3. Immunostaining of VILIP-1 in
amygdala and hypothalamus is considerably weaker than in
hippocampus, whereas intense staining is observed in the
cerebellum and in vestibular and trigeminal neurons of the
brainstem. VILIP-1 in a rat model of ischemic stroke can be
elevated at both the mRNA and protein levels at 24 hour
post-injury.
The step of determining the presence of a visinin-like
protein is also not particularly limited. In some embodiments the presence of a visinin-like protein can be determined via an enzyme-linked immunosorbent assay (ELISA).
In other embodiments the detecting step is performed via a
novel lateral flow device that comprises one or more antibodies that are specific for the visinin-like protein, as
described further below. Thus, the determining step can
include detecting a measurable presence of a visinin-like
protein in a substance.
In some embodiments the presence of a visinin-like
protein is established if it is determined that the sample
includes any measurable amount of the visinin-like protein.
In other embodiments the presence of a visinin-like protein
is established only if the visinin-like protein is present at a
particular concentration and/or range of concentrations. In
some embodiments the presence of a visinin-like protein is
established if the visinin-like protein is present at concentration of 100 ng/ml or more, 200 ng/ml or more, 300 ng/ml
or more, 400 ng/ml or more, 500 ng/ml or more, 600 ng/ml
or more, 700 ng/ml or more, 800 ng/ml or more, 900 ng/ml
or more, 1,000 ng/ml or more, 2,000 ng/ml or more, 3,000
ng/ml or more, 4,000 ng/ml or more, 5,000 ng/ml or more,
6,000 ng/ml or more, 7,000 ng/ml or more, 8,000 ng/ml or
more, 9,000 ng/ml or more, or 10,000 ng/ml or more. In yet
other embodiments, as described herein, the concentration of
a visinin-like protein can indicate the disease or condition
that has or is causing brain damage in a subject.
For example, the present methods for diagnosing and/or
prognosing may be used for any brain damage. Types of
brain damage that can be diagnosed and/or prognosed with
the present methods include, but is not limited to, brain
damage caused by a traumatic brain injury (TBI), including
mild, moderate, or severe TBI, a stroke, including hemorrhagic stroke or ischemic stroke, a seizure, a migraine, a
syncope, and the like. In some embodiments the brain
damage can include brain damage due to neuronal damage,
hypoxic damage, or both. Thus, the present methods can
provide a relatively simple and noninvasive way to identify
brain damage caused by a wide range of diseases, conditions, and events for a variety of subjects. In some embodiments the subject includes a premature infant, and the brain
damage being diagnosed, prognosed, and/or treated can
include neuronal damage, hypoxic damage, and combinations thereof.

In this regard, embodiments of the present methods can be
used to determine the severity of brain damage, and optionally can determine the severity of the brain damage as a
function of time. For example, embodiments may be able to
categorize a TBI as being mild, moderate, or severe based on
the concentration of a visinin-like protein in a sample. Thus,
in some embodiments the present methods are performed on
a subject known or suspected as having a TBI, and in some
embodiments is performed about 1 minute to about 24 hours
after an event that caused or is suspected of having caused
TBI. In some embodiments, a concentration of at least about
200 ng/ml of a visinin-like protein (e.g., VILIP-1) in a
sample obtained from a subject one hour post injury indicates that the subject has experienced mild TBI, and for
some subjects a concentration of at least about 500 ng/ml of
the visinin-like protein-! one hour post injury indicates that
the subject has experienced moderate TBI. In some embodiments where a sample is obtained from a subject three hours
post injury, a concentration of about 200 ng/ml to about 800
ng/ml of a visinin-like protein in the sample indicates that
the subject experienced a mild TBI, and in other embodiments a concentration of about 800 ng/ml or more of a
visinin-like protein in the sample indicates that the subject
experienced moderate TBI.
Other embodiments of the present methods can categorize
a stroke as being either ischemic or hemorrhagic and/or can
categorize the stroke as being mild, moderate, or severe
based on concentration of a visinin-like protein present in a
sample. In some embodiments a subject can be diagnosed
has having experienced an ischemic stroke if the subject
exhibits a presence of a visinin-like protein at a concentration that is below a concentration of visinin-like protein
expressed in subjects with TBI, including mild TBI, and
hemorrhagic stroke. On the other hand, in some embodiments a subject can be diagnosed has having experienced an
hemorrhagic stroke if the subject exhibits a presence of a
visinin-like protein at a concentration that is approximately
equal to or above a concentration of visinin-like protein
expressed in subjects with mild TBI.
In specific embodiments the presence of the visinin-like
protein at a concentration of about 100 ng/ml to a concentration of about 400 ng/ml in the sample is indicative of
ischemic stroke, whereas the presence of the visinin-like
protein in excess of about 700 ng/ml in the sample is
indicative hemorrhagic stroke. In some embodiments the
present methods are performed on subjects known or suspected to have experienced a stroke. In yet other specific
embodiments, wherein the subject is a human known or
suspected of having experienced a stroke, a presence of the
visinin-like protein below about 5,000 ng/ml in a sample
obtained from the subject is indicative of ischemic stroke,
and a presence of the visinin-like protein above about 5,000
ng/ml in a sample obtained from the subject is indicative of
hemorrhagic stroke. In some instances the methods are
performed about 1 minute to about 24 hours after the known
or suspected stroke in order to provide a clinically relevant
diagnosis and/or prognosis.
Additionally, embodiments of the methods and systems
described herein can diagnose and/or prognose a subject
with brain damage and/or a particular type of brain damage
relatively quickly by determining the presence of a visininlike protein in a sample collected from a subject. The
relatively rapid diagnosis and/or prognosis can permit relevant treatments to be administered to a subject in need soon
after the occurrence of brain damage, potentially increasing
the effectiveness of the administered treatment. For
example, in the case of subjects believed to have potentially
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have suffered a stroke, it can be beneficial to delineate
whether the subject has had an ischemic stroke or a hemorrhagic stroke as soon as possible, and in some instances
within two hours of the event believed to have been a stroke.
Generally, outcomes are superior if treatment can be administered for an ischemic stroke within this early time frame.
Generally, treatment for ischemic stroke (e.g., thrombolytic
treatment) cannot be administered until one is diagnosed
with ischemic stroke, particularly if there is a risk that the
subject might otherwise have a TBI or hemorrhagic stroke.
In some embodiments a determination regarding the presence of a visinin-like protein can be made in about 15
minutes or less following obtaining a sample. Regardless of
the time required to make such a determination, embodiments of the presently-disclosed methods can provide a
diagnosis and/or prognosis in less than about 24 hours, in
less than about 6 hours, in less than about 4 hours, in less
than about 3 hours, in less than about 2 hours, and in less
than about 1 hour following obtaining a sample. In specific
embodiments, the present methods and systems can provide
a diagnosis and/or prognosis within about 1 to about 30
minutes, or within about 1 to about 15 minutes. This
characteristic of embodied methods can be beneficial
because visinin-like protein levels can be altered in blood as
soon as 1 hour following TBI or ischemic stroke.
In certain embodiments of the presently-disclosed subject
matter, a method for diagnosing and/or prognosing brain
damage in a subject is provided, wherein the method comprises providing a biological sample obtained from the
subject, exposing the sample to an antibody that is selective
for a visinin-like protein, detecting the presence of a complex that includes the antibody and the visinin-like protein,
and diagnosing and/or prognosing the subject as having
brain damage if there is a presence of the complex. The
terms "selective for," "selectivity," and the like are used
herein to refer to a characteristic of a molecule that preferentially and/or exclusively binds a target molecule. Selectivity can be imparted by the charge, conformation, and/or
functional groups of the selective molecule. It will be
understood that certain antibodies can selectively bind to
target proteins.
Alternatively or additionally, in some embodiments the
antibody utilized in the present methods is provided as a
conjugate that includes the antibody that is selective for the
visinin-like protein and a detection probe. Subsequently, the
detecting step includes detecting the presence of a complex
that includes the visinin-like protein and the conjugate,
which itself includes the antibody conjugated to the detection probe. Detection probes may be selected from those
known in the art, including fluorescent compounds, radioactive compounds, nanobeads, visual labels, or combinations thereof. In some embodiments the nanobeads are
nanogold beads.
In other embodiments of the present methods for the
diagnosis and/or prognosis of brain damage in a subject, the
methods can comprise providing a biological sample
obtained from the subject, determining a presence of two or
more visinin-like proteins in the subject, and diagnosing
and/or prognosing the subject as having brain damage if
there is the presence of the two or more visinin -like proteins.
The two or more visinin-like proteins can be selected from
VILIP-1, VILIP-2, VILIP-3, hippocalcin, neurocalin delta,
and combinations thereof. In some embodiments at least one
of the two or more visinin-like proteins includes VILIP-1.
Treatment
The presently-disclosed subject matter also provides
methods for treating brain damage in a subject. Exemplary

methods can comprise a step of providing a biological
sample obtained from the subject, a step of determining a
presence of a visinin-like protein in the subject, wherein the
presence of the visinin-like protein indicates that the subject
has brain damage, and a step of administering a treatment for
brain damage if the subject includes the presence of the
visinin-like protein. Accordingly, some embodiments can
comprise a step of treating brain damage if the subject is
diagnosed and/or prognosed as having brain damage.
The terms "treatment" or "treating" refer to the medical
management of a subject with the intent to cure, ameliorate,
stabilize, or prevent a disease, pathological condition, or
disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a
disease, pathological condition, or disorder, and also
includes causal treatment, that is, treatment directed toward
removal of the cause of the associated disease, pathological
condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of
symptoms rather than the curing of the disease, pathological
condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely
inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that
is, treatment employed to supplement another therapy
directed toward the improvement of the associated disease,
pathological condition, or disorder.
The term "administering" is not particularly limited, and
refers to any method of providing a composition and/or
pharmaceutical composition thereof to a subject. Such methods are well known to those skilled in the art and include, but
are not limited to, oral administration, transdermal administration, administration by inhalation, nasal administration,
topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral
administration, rectal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration,
subcutaneous
administration,
intravitreous
administration, intracameral (into anterior chamber) administration, subretinal administration, sub-Tenon's administration, peribulbar administration, administration via topical
eye drops, and the like. Administration can be continuous or
intermittent. In various aspects, a preparation can be administered therapeutically; that is, administered to treat an
existing disease or condition. In further various aspects, a
preparation can be administered prophylactically; that is,
administered for prevention of a disease or condition.
In some embodiments the subject is diagnosed and/or
prognosed with a certain type of brain damage so that an
appropriate treatment can be administered. For example,
some embodiments of the present treatment methods comprise administering to the subject a treatment for TBI,
hemorrhagic stroke, or ischemic stroke if the subject is
diagnosed with, respectively, TBI, hemorrhagic stroke, or
ischemic stroke. In some embodiments the treatment for
ischemic stroke can include a thrombolytic therapy. The
thrombolytic therapy can include administration of compounds selected from the group consisting of warfarin,
aspirin, and thrombolytic drugs such as tissue plasminogen
activators (e.g., alteplase, reteplase, tenecteplase ), anistreplase, streptokinase, urokinase, and any other thrombolytic
therapies known in the art.
The present treatment method can also comprise steps of
altering treatments depending on the severity of the brain
damage or the disease, condition, or event that caused the
brain damage. For instance, in some embodiments the
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present methods include a step of characterizing the severity
of an ischemic stroke depending on the concentration of the
visinin-like protein that is present in the sample provided
from the subject. Thereafter, the severity of the diagnosed
ischemic stroke can also be used to direct and optimize
treatment of the ischemic stroke.
Device
The presently-disclosed subject matter provides devices
for detecting the presence of a visinin-like protein in a
sample. In some embodiments the device is a lateral flow
device (LFD). In some embodiments the lateral flow device
can further comprise a vertical flow device. Exemplary
devices can be stable at room temperature, and some devices
can be stored for extended periods for future use.
In this respect, typically it can take up to 24 hours to
quantifY levels of the protein of interest using ELISAs. This
relatively long time period is outside potentially therapeutic
windows for many types of brain damage, including certain
types of stroke and TBI. On the other hand, the present
devices include lateral flow devices and vertical/lateral flow
devices that allow for more rapid quantification of biomarkers (e.g., visinin-like protein) in subjects having or suspected
of having TBI, stroke, or other brain damage. In general,
lateral flow devices use material(s) that cham1el analytes
(i.e., visinin-like proteins) into close proximity with target
substances, such as antibodies, and can allow reaction and
binding of the target substance to the analytes. Lateral
movement of the sample in the lateral flow device allows for
its controlled interaction with agents (e.g., antibodies) which
can be located along the test cham1el(s), thereby allowing
control of sequencing and timing of interactions.
The present lateral flow devices can employ passive
means, such as capillary forces, of fluid movement that is not
aided by a fluid pump. The present lateral flow devices can
comprise natural or synthetic lateral flow materials. The
materials can have porous structures that induce capillary
forces. In some embodiments the lateral flow devices comprise capillary tubes or channels to direct flow. Exemplary
materials for the devices include, but are not limited to,
polysaccharides (e.g., cellulose materials such as paper and
cellulose derivatives, such as cellulose acetate and nitrocellulose), polyether sulfone, polyethylene, nylon, polyvinylidene fluoride (PVDF), polyester, terephthalate (polyester) (PET), polymethylmethacrylate (PMMA), polystyrene,
polypropylene, silica, inorganic materials, such as deactivated alumina, glass, diatomaceous earth, MgS04 , ceramics,
or other inorganic finely divided material uniformly dispersed in a porous polymer matrix, natural and/or synthetic
cloth (e.g., cotton, nylon, or rayon), porous gels, such as
silica gel, agarose, dextran, and gelatin, polymeric films,
such as polyacrylamide; and the like.
The devices described herein can provide an efficient,
accurate, and expedient manner in which to determine the
presence of a visinin-like protein in a biological sample
collected from a subject, and then potentially use this
determination to make a diagnosis and/or prognosis within
a clinically relevant time. In some embodiments the present
devices can provide a diagnosis and/or prognosis within
about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes,
6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15
minutes, 20 minutes, or 30 minutes of applying a sample to
the device. In some embodiments the present devices can
provide a diagnosis and/or prognosis in about 1 hour or less,
about 2 hours or less, about 3 hours or less, about 4 hours or
less, about 5 hours or less, or about 6 hours or less.
The present devices can be configured to detect a visininlike protein in a sample at a minimum concentration or

within a range of concentrations. The devices can thus detect
the presence of a visinin-like protein so that the device can
be utilized to diagnose and/or prognose a subject with brain
damage or specific sources of brain damage such as TBI or
a stroke. Some embodiments of the present devices can
detect the presence of the visinin-like protein in a sample at
a concentration of at least about 20 ng/ml or more. Some
embodiments of the present devices can detect the presence
of the visinin-like protein in a sample at a concentration of
about 100 ng/ml, 200 ng/ml, 300 ng/ml, 400 ng/ml, 500
ng/ml, 600 ng/ml, 700 ng/ml, 800 ng/ml, 900 ng/ml, 1,000
ng/ml, 2,000 ng/ml, 3,000 ng/ml, 4,000 ng/ml, 5,000 ng/ml,
6,000 ng/ml, 7,000 ng/ml, 8,000 ng/ml, 9,000 ng/ml, 10,000
ng/ml, or more.
In some embodiments the device includes a sample portion, a conjugate portion, and a detection portion. Optionally, in some embodiments a wicking portion is provided
downstream of the conjugate portion and is intended to
collect any residual sample that flows through the device and
past the detection portion. The sample portion, conjugate
portion, detection portion, and wicking portion of embodied
devices can be comprised of one continuous piece of a
material or can be comprised of two or more distinct
materials that may or may not be of the same type as one
another. For example, the detection portion and the wicking
portion can be formed from one continuous material,
wherein the detection portion and wicking portion refer to
different sections the piece of material, and in other embodiments the detection portion and the wicking portion can be
comprised of two distinct materials.
The sample portion is provided to receive a sample. In
some embodiments the sample portion can further receive a
substance that permits the biological sample to cross through
the device, such as a buffer solution (e.g., PBS). In some
embodiments the biological samples comprise about 10 f.LL
to about 1000 fll of a liquid sample.
Exemplary sample portions can further comprise an albumin eliminator for removing albumin from the biological
sample, wherein "albumin eliminator" refers to any material,
substance, or means for removing albumin from a substance.
When the biological sample is whole blood or serum,
embodiments of the sample portions can remove cells from
the biological sample before it progresses to the other
portions and membranes of the device. The cell and/or
albumin removing means prevent the red blood cells or
albumin from interfering with the test procedure and can
help ensure that readings for the presence of a visinin-like
protein are accurate. For example, red blood cells typically
constitute about half of the volume of a blood sample.
Unless the red blood cells are substantially removed, their
presence can affect certain results that are sensitive to color.
Hemoglobin can also interfere chemically with certain methods, and is removed by in some embodiments of the present
methods and devices.
In some embodiments plasma is separated from red blood
cells is by centrifugation prior to applying the sample to a
device. Other exemplary methods for removing red blood
cells are described in U.S. Pat. No. 4,477,575, which is
incorporated herein by reference, and describes a blood filter
made from glass fiber that can separate out red blood cells
when whole blood is slowly trickled onto one side. Unsaturated aliphatic fatty acid or an ester thereof can also be
provided in some devices, including on the sample portion
of some devices, and can induce the formation of red blood
cells that are distorted in shape and less flexible and malleable than normal red blood cells, making them less able to
penetrate and flow through the device. The stiffer, less
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flexible cells cannot move easily and become trapped, while
the liquid components of the sample can flow through the
device and penetrate the detection portion for analysis.
Those of ordinary skill will recognize other means and
substances for removing red blood cells and other interfering
substances from a sample that is intended for detecting a
visinin-like protein.
The device further comprise a conjugate portion downstream of the sample portion that includes a conjugate. The
conjugate can be disposed on a surface of the conjugate
portion, impregnated into the conjugate portion, or the like.
The conjugate includes a first antibody that is selective for
the visinin-like protein that is bound (conjugated) to a
detection probe. The first antibody and the detection probe
can be bound by any means, including covalent bonds,
electrostatic, bonds, other physical interactions, and the like.
The conjugate can be deposited along with one or more
supporting substances. These supporting substances include,
but are not limited to, poly (ethylene glycol) (PEG), sugars
(i.e. dextran, maltodextrose), and surfactants, such as nonionic surfactants (e.g., polysorbate 20 or 80, Triton X-100).
Supporting substances can be added for a range of purposes,
such as to reduce non-specific interactions between the
sample and the device, obtain desired flow velocity, and to
control the stability, viscosity, and release of the conjugate
material.
The first antibody that comprises the conjugate can be of
any class and be have dual or multiple antigen or epitope
specificities. The first antibody can be a polyclonal antibody,
particularly a humanized or an affinity-purified antibody
from a human. The first antibody can be an antibody from an
appropriate animal; e.g., a primate, goat, rabbit, mouse, or
the like. If a paratope region is obtained from a non-human
species, the target may be humanized to reduce immunogenicity of the non-human antibodies, for use in human
diagnostic, prognostic, or therapeutic methods. Such a
humanized antibody or fragment thereof can also be termed
"chimeric." For example, a chimeric antibody includes
non-human (e.g., murine) variable regions and human constant regions. Monoclonal antibodies are also suitable. A first
antibody can include genetically engineered and/or recombinant proteins, whether single-chain or multiple-chain,
which incorporate an antigen-binding site and otherwise
function in vivo as immobilized target-binding moieties.
The first antibody can be selective for a visinin-like
protein. In this manner, when a sample comprising a visininlike protein is applied to a device, the conjugate will bind to
the visinin-like protein via the first antibody, thereby labeling the visinin-like protein with the detection probe-labeled
conjugate. The first antibody can be selective for one or
more portions of the visinin-like protein, and in some
embodiments is selective for the N-terminus, the C-terminus, or both of a visinin-like protein.
The detection probes are not particularly limited, and
include substances that are detectable either visually or by
an instrumental device. Exemplary detection probes can
include, but are not limited to, fluorescent compounds (e.g.,
fluorescent, phosphorescent, etc.), radioactive compounds,
visual labels (e.g., colored dye or metallic substance), liposomes or other vesicles containing signal-producing substances; enzymes and/or substrates, and combinations
thereof. The detectable substance can be in the form of a
particle, such as a nanobead. Exemplary particles include
naturally occurring particles, such as nuclei, mycoplasma,
plasmids, plastids, mammalian cells, unicellular microorganisms, polysaccharides, and the like. Exemplary particles
can also be synthetic particles, such as particles comprised

of polystyrene, butadiene styrenes, styreneacrylic-vinyl terpolymer, polymethylmethacrylate, polyethylmethacrylate,
styrene-maleic anhydride copolymer, polyvinyl acetate,
polyvinylpyridine,
polydivinylbenzene,
polybutyleneterephthalate, acrylonitrile, vinylchloride-acrylates, and the
like. Exemplary particles also include metallic substances,
and in some embodiments the conjugate comprises nanogold
beads conjugated to a first antibody that is selective for the
visinin-like protein.
The present devices further include a detection portion
disposed along the flow path that include one or more
immobilized targeting substances selective for the conjugate
and/or the visinin-like protein. In some embodiments the
detection portion comprises a second antibody that is selective for the visinin-like protein, and in some instances the
first antibody and the second antibody are selective for
different portions of the visinin-like protein. Thus, samples
that migrate from the sample portion can remain in the
detecting portion if the samples include a visinin-like protein
that binds to the immobilized second antibody. Likewise, if
the visinin-like protein binds to a conjugate having the
detection probe and the first antibody, then the resulting
complex will remain in the detecting zone when the visininlike protein binds to the second antibody.
The detection portion can also comprise a control zone
that includes a third targeting substance (e.g., third antibody)
that is selective for the first antibody. As discussed above,
the first antibody is conjugated to a detection probe. Thus, if
the conjugate does not bind to a visinin-like protein, it can
pass across the second antibody and bind to the control zone.
Detection of the conjugate that includes the first antibody
and the detection probe on the control zone indicates that a
sample flowed through the device but contained little to no
visinin-like protein.
The targeting substances (e.g., second antibody and third
antibody) can be immobilized in the detection zone as
stripes. In this manner, a presence of the visinin-like protein
can be detected if a complex including the conjugate and
visinin-like protein bind to a location corresponding to the
second antibody stripe. Similarly, a presence of the conjugate in a stripe corresponding to the control zone (e.g., third
antibody) indicates the positive control line for the device.
An exemplary lateral flow device is shown in FIG. 1. The
lateral flow device in FIG. 1 comprises a sample portion (E)
that is upstream of a conjugate portion (D), which itself
includes nanogold labeled first antibodies that can selectively bind a visinin-like protein. The nanogold labeled first
antibody/antigen complex can then migrates along a detection portion (B) that is comprised of a separation membrane.
The complex can be trapped by a second antibody against an
alternate portion of the visinin-like protein as a thin stripe
near the termination of the separation membrane. In addition
to rapid reaction times between the visinin-like protein and
the first antibody, the embodied lateral flow device offers the
advantage of inclusion of additional membranes for cell
separation and for removal of potentially interfering proteins
(e.g, albumin).
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The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples
set forth below. The examples may include compilations of
data that are representative of data gathered at various times
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during the course of development and experimentation
related to the presently-disclosed subject matter.

at 60 ug/cm and dried for 1 hr at 37° C. Albumin eliminator/
sample portions were stored in sealed bags with desiccant at
room temperature.
The stored and/or treated membranes were then
assembled into the lateral flow device. First, a 16 mm wide
Whatman 470 wicking portion (GE Healthcare Life Sciences) was overlaid at the top of the cellulose nitrate
membrane (detection portion) parallel to the test and control
lines and was attached to the laminate backing. A 13 mm
conjugate portion was overlaid at the bottom of the cellulose
nitrate parallel to the test and control lines and was attached
to laminate backing 2 mm from the bottom of the test strip.
A 15 mm sample portion was adhered to the bottom of the
test strip overlaying the conjugate portion. The Assembled
membranes were cut into 4 mm wide strips and fitted into
MICA-010 2-hole cassettes (Diagnostic Consulting Network, Carlsbad, Calif.) assemblies. Assembled lateral flow
devices were stored in sealed sample bags with desiccant at
room temperature for future use.

Example 1
5

This Example describes a method for preparing a lateral
flow device for detecting the presence of VILIP-1 in a
biological sample. As shown in FIG. 1, the lateral flow
device comprises of a combination of membranes that
remove cells (e.g., whole blood) and serum albumin (e.g., rat
or human) from a biological sample, nanogold labeled anti
VILIP-1 raised against the N terminus of human VILIP-1,
and a narrow line near the terminal end of anti-VILIP-1
antibody raised against the C terminus of human VILIP-1.
More specifically, and still referring to FIG. 1, the lateral
flow device comprised a laminate backing (A; MIBA-010;
Diagnostic Consulting Network, Carlsbad, Calif.), a sample
portion for receiving a biological sample (E; Vivid Plasma
Separation-GX; Pall Corporation, Port Washington, N.Y.), a
conjugate portion (D; Pall, Grade 896), a detection portion
(B; Unisart CN140 Nitrocellulose Membrane, 42 mm; Sartorius Stedin North America Inc, Bohemia, N.Y.), and a
wicking portion (C; Whatman 470; GE Healthcare Life
Sciences, Piscataway, N.J.).
To prepare the antibodies, all antibodies were dialyzed
against water overnight at 4° C., lyophilized, and re-suspended in lx PBS (pH 7.4) at concentrations described in
this Example. Next, monoclonal VILIP-1 PL-A2 (Abnova,
Taipei City, Neihu District, Taiwan) at a concentration of 2
mg/mL was conjugated to 40 nm go! sol per manufacturers'
instructions (BioAssay Works, Fredrick, Md., USA) with
modification. Briefly 6 flg of VILIP-1 PL-A2 was conjugated with 0.5 mL of 40 nm Naked Gold Sol (OD 7.5) for
5 min at room temperature with constant gentle agitation.
Conjugation was stopped by the addition of 10% BSA
solution for 1 hr at room temperature with constant agitation
followed by the treatment with N-ethylmalemide at a final
concentration of 20 nM for 1 hr at room temperature with
constant agitation.
The antibody-nanogold conjugate was then added to the
conjugate portion. Specifically, the mouse anti-VILIP-1
PL-A2/nanogold conjugate was mixed with 25% sucrose/
1% Tween 20 in PBS and Rabbit anti-goat IgG Dressed Gold
(BioAssay Works) in a 1:0.6:1.7 ratio and applied to 25%
sucrose/!% Tween 20 in PBS pre-coated at 10 uL/cm Pall
Grade 8964 conjugate portion (Pall, Port Washington, N.Y.,
USA) using an Air-Jet sprayer (BioDot, Irvine, Calif., USA)
at a volume of 70 uL/cm and dried for 1 hr at 37° C.
Conjugate portions were stored in sealed sample bags with
desiccant at room temperature.
Next, the Unistart CN140 cellulase nitrate membranes
(detection portion) were applied to the MIBA-010 laminate
backing Rabbit anti-VILIP-1 K-25 (Santa Cruz Biotechnology, Santa Cruz, Calif.) at a final concentration of 0.5
mg/mL and Goat Serum (Invitrogen, Carlsbad, Calif.,) were
applied in parallel stripes using Bio-Jet equipment (BioDot)
at 4 ug/cm and 16 uL/cm and 30 and 37 mm from the bottom
of the lateral flow device, respectively. The membranes were
dried for 1 hr at 3 7° C. blocked in 1% dry milk/PBS for 15
minutes, washed 3 times in PBS, and dried for 1 hr at 37° C.
Backed cellulose nitrate membranes were stored in sealed
sample bags with desiccant at room temperature.
Sheep anti-rat (Bethyl Laboratories, Montgomery, Tex.,
USA; 4 mg/mL) or anti-human albumin (Santa Cruz) was
then applied to the Vivid Plasma Separation-GX (Pall Corporation) sample portions using a Bio-Jet sprayer (BioDot)
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This Example describes procedures conducted to evaluate
how the embodiments of lateral flow devices that were
prepared in Example 1 can be used to detect the presence of
VILIP-1 in subjects having brain damage, including brain
damage caused by ischemic stroke or TBI.
First, using recombinant VILIP-1 as a standard protein, a
limit of detection of 0.2 ng/ml serum and a linear response
between 0.2 ng/ml and 7.0 ng/ml was detected (r=0.91).
FIG. 2 shows levels ofVILIP-1 in normal control serum are
below the limit of detection. Thus, the lateral flow devices
were capable of detecting the presence of VILIP-1 in biological samples.
To determine if serum VILIP-1 levels change in due to
ischemic stroke, animals were subjected to a 1 hour middle
cerebral artery occlusion (MCAO) using the Zea Longa
method. Specifically, nine three-month-old Sprague-Dawley
rats (250-300 g) were subjected to a 1 hour ischemic event
induced by suture occlusion of the middle cerebra artery.
Control animals (N=5) were subjected to surgical preparation but without occlusion. Blood samples (50 f.LL) were
obtained from the left femoral artery prior to occlusion,
when the occlude was removed (pre-reperfusion), 15 minutes after initiation of reperfusion, and 24 hour post reperfusion.
To examine serum levels ofVILIP-1 in TBI, four 3 month
old Sprague-Dawley rats were subjected to mild or moderate
controlled cortical impact (CCI) or sham surgery in which a
portion of the skull was removed but without brain impact.
Control rats consisted of surgery naive rates (N=4) anesthetized but without any surgical manipulation. For analyses,
whole blood (100-200 f.LL) samples were taken prior to
beginning surgeries and 1, 2, and 3 hour post injury from tail
nicks of the young adult male Spraque-Dawley rats under
isoflurane anesthesia (2% ).
Immediately following collection, whole blood (1 0 f.LL) or
serum (10 f.LL) samples were applied to the asymmetric
sample portion, resulting in the removal of red blood cells
from the sample. Three minutes post sample loading 20 f.LL
of lateral flow device sample buffer (0.5% Surfactant 1OG,
0.8 USP heparin/mL) was applied directly to the conjugate
portion to prevent lysis of red blood cells trapped in the
asymmetrical sample portion and facilitate migration of the
sample through the cellulose nitrate membrane. The test and
control lines were observed for color development at 15
minutes post-sample loading, and images were captured for
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analysis. Gold Enhance LM/Blot (Nanoprobes, Yaphank,
N.Y., USA) was prepared per manufacturer's directions and
20 f.LL was applied directly to the lateral flow device membranes. Color development was observed 15 minutes postcolor enhancement and images were taken for analysis. The
remaining whole blood samples were centrifuged at
15,000xg for 5 minutes and the serum samples were collected and stored at -80° C. for later analysis.

with hemorrhagic stroke and two subjects with ischemic
stroke and showed mean±SD concentrations of
1988.7±714.4 ng/ml for the ischemic stroke patients and
7125.8±1254.1 ng/ml for subjects with hemorrhagic stroke.
The measured values were positively related to infarct
volume measured by MRI (FIG. 9).
It will be understood that various details of the presently
disclosed subject matter can be changed without departing
from the scope of the subject matter disclosed herein.
Furthermore, the description provided herein is for the
purpose of illustration only, and not for the purpose of
limitation.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth herein to facilitate explanation of the presentlydisclosed subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are described herein.
The terms "comprising", "including," and "having" are
intended to be inclusive and mean that there may be additional elements other than the listed elements.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a protein" includes a plurality of such proteins, and
so forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1 %, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations
are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
Throughout this document, various references are mentioned. Such references include, but are not limited to,
publications, patents, and patent applications. All such references are incorporated herein by reference, including the
references set forth in the following list:

Example 3
This Example describes the relationship between VILIP-1
levels and brain damage that were observed using the
procedures described in Example 2. Specifically, this
Example describes how VILIP-1 levels were affected by the
induced ischemic stroke and TBI in rat subjects.
As described above, whole blood (10 f.LL) were analyzed
at the time of draw and the remaining blood samples were
centrifuged to prepare serum which was analyzed from all
time points later. FIG. 3 shows that levels of VILIP-1 in
serum were considerably higher in mild TBI compared to
ischemic stroke 1 hour and 15 minutes post injury, thereby
suggesting that TBI can induce more pronounced neuronal
injury (i.e., brain damage). Without being bound by theory
or mechanism, VILIP-1 levels for subjects having experienced hemorrhagic stroke can be comparable to those
observed in TBI because hemorrhagic stroke can cause
severe tissue damage. Thus, optionally when combined with
clinical presentation, the presence of VILIP-1, including at
concentrations below a level corresponding to TBI or hemorrhagic stroke, can provide a delineation of ischemic stroke
from hemorrhagic stroke.
With regard to the rats having the induced ischemic
stroke, FIG. 4 shows serum levels of VILIP-1 increased
significantly immediately after the occlude was removed.
FIG. 4 also suggests that serum levels ofVILIP-1 reached a
maximum after initiation of reperfusion, and remained
elevated 24 hours post injury. Correlation analyses showed
VILIP-1 levels were significantly correlated (r=0.61) with
lesion volume measured 24 hour post-injury. FIG. 5 shows
receiver operating characteristic (ROC) curves for VILIP-1
levels at each time point and shows sensitivity/specificity
values of 89 and 75% with an area under the curve (AUC)
of 86% for 15 minutes post reperfusion and 100% sensitivity/75% specificity and an AUC=97% for 24 hours post
reperfusion.
For the rats subjected to TBI, FIG. 6 shows mean±SEM
serum VILIP-1 levels, and shows that VILIP-1 levels in
serum progressively increased 1 hour, 3 hours, and 4 hours
post injury for both mild TBI and moderate TBI test groups.
FIG. 7 shows ROC for VILIP-1 in the subjects having mold
TBI and moderate TBI.

10

15

20

25

30

35

40

45

50

Example 4
55

This Example describes a diagnostic procedure conducted
on human samples using the methods and device described
in Examples 1 and 2.
Serum samples from a commercial source that were taken
from patients 6 hours after ischemic (N=2) or hemorrhagic
(N=2) stroke. Serum samples (10 fll) were applied to LFDs
as described above, and intensity of the trapped nanogold
was quantified using Scion Image Analysis. Quantification
of VILIP-1 levels was carried out using a calibration curve
constructed using increasing concentrations of standard
VILIP-1 prepared in 70% control serum. FIG. 8 shows
results of the analysis of serum samples from two subjects
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What is claimed is:
1. A lateral flow device for detecting a presence of
VILIP-1 protein in a biological sample, comprising:
a sample portion for receiving the biological sample,
wherein the sample portion removes red blood cellsa conjugate portion downstream of the sample portion th~t
includes a conjugate, the conjugate including a first
antibody conjugated to a detection probe, wherein the
first antibody is selective for a first portion ofVILIP-1,
wherein the first portion is not a C-terminal portion of
VILIP-1; and,
a detection portion downstream of the conjugate portion
that includes a second antibody that is selective for a
second portion ofVILIP-1, wherein the second portion
is a C-terminal portion of VILIP-1.
2. The device of claim 1, wherein the sample portion
further comprises a buffer solution.
3. The device of claim 1, wherein the detection probe is
selected from a fluorescent compound, radioactive compound, a visual label, nanobeads and combinations thereof.
4. The device of claim 1, wherein the sample portion
comprises a material for removing red blood cells selected
from the group consisting of: asymmetric polysulfone, glass
fiber filter, or unsaturated aliphatic fatty acid or ester thereof.
5. The device of claim 3, wherein the nanobeads are
nanogold beads.
6. The device of claim 1, wherein the detection zone
further comprises a control zone comprising a third antibody
selective for the first antibody.
7. The device of claim 1, wherein the second or third
antibody are immobilized in the detection zone as a stripe at
a concentration of 4 f.tg/cm.
8. The device of claim 1, wherein the antibodies of the
conjugate zone are immobilized on a conjugate pad.
9. The device of claim 1, wherein the detection zone
comprises a nitrocellulose membrane.
10. The device of claim 1, further comprising a wicking
portion.
11. The device of claim 1, wherein the first anti-VILIP-1
antibody associated with a detection probe is deposited with
one or more supporting substances.
12. A method of detecting VILIP-1 protein in a biological
sample, comprising
providing a biological sample to a sample portion
upstream of a conjugation zone of a separation membrane, wherein the sample portion removes red blood
cells from the biological sample and wherein the conjugation zone comprises a first antibody selective for a
non C-terminal portion of VILIP-1 associated with a
detection probe immobilized thereon such that the
VILIP-1 protein, if present in the biological sample,
form a first antibody and VILIP-1 complex; and
migrating the first antibody and VILIP-1 complex along
the separation membrane to a detection zone compris-

ing a second antibody selective for a C-terminal portion
of VILIP-1 immobilized thereon, wherein the second
anti-VI LIP -1 antibody captures the first antibody and
VILIP-1 complex resulting in detectable signals indicative of the presence and/or amount of the VILIP-1
protein in the biological sample.
13. The method of claim 12, wherein the detectable
signals occur within a period of time less than 15 minutes
from providing the biological sample to the separation
membrane.
14. The method of claim 12, wherein the biological
sample is a blood sample, a serum sample, or a plasma
sample.
15. The method of claim 12, wherein the biological
sample is 10 fll or less in volume.
16. The method of claim 12, wherein the sample portion
comprises a material for removing red blood cells selected
from the group consisting of: asymmetric polysulfone, glass
fiber filter, or unsaturated aliphatic fatty acid or ester thereof.
17. The method of claim 12, wherein the biological
sample is obtained from a subject suspected of suffering a
brain injury or trauma.
18. The method of claim 17, wherein the biological
sample is obtained from the subject within 60 minutes after
suspected brain injury or trauma.
19. The method of claim 17, wherein the brain injury or
trauma is neuronal damage, hypoxic damage or combinations thereof.
20. The method of claim 17, wherein the subject is a
premature infant.
21. The method of claim 17, wherein the brain injury or
trauma is stroke.
22. The method of claim 21, wherein the stroke is
hemorrhagic or ischemic.
23. The method of claim 17, wherein the brain injury or
trauma is traumatic brain injury (TBI).
24. The method of claim 23, wherein based on the
concentration of VILIP-1 protein the TBI can be diagnosed
as mild, medium or severe.
25. The method of claim 12, wherein the concentration of
the VILIP-1 protein in the biological sample is less than 500
ng/ml.
26. The method of claim 12, wherein the detection probe
may be selected from the group comprising fluorescent
compounds, radioactive compounds, nanobeads, visual
labels, or combinations thereof.
27. The method of claim 26, wherein the nanobeads are
nanogold beads.
28. The device of claim 1, wherein one or both of the first
portion and the second portion is or comprises a conformation of VILIP-1.
29. The device of claim 1, wherein the first portion is that
recognized by antibody PL-A2 and/or the second portion is
that recognized by antibody K-25.
30. The device of claim 1, wherein the first antibody is or
comprises PL-A2 and or wherein the second antibody is or
comprises K-25.
31. The method of claim 12, wherein one or both of the
first portion and the second portion is or comprises a
conformation of VILIP-1.
32. The method of claim 12, wherein the first portion is
that recognized by antibody PL-A2 and/or the second portion is that recognized by antibody K-25.
33. The method of claim 12, wherein the first antibody is
or comprises PL-A2 and or wherein the second antibody is
or comprises K-25.
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